×
About 106,912 results
Commonly Abused Drugs Charts
https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts
NIH

Nov 9th, 2019 - Many misused drugs can alter a person’s thinking and judgment, leading to health risks, including addiction, drugged driving and infectious disease. Most drugs could potentially harm an unborn baby; pregnancy-related issues are listed in the chart below for drugs where there is enough scientific evidence to connect the drug use to specific negative effects. Commonly Abused Drugs.

FDA approves new antibiotic to treat community-acquired bacterial pneumonia
https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia

Aug 18th, 2019 - The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. “This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease,” said Ed Cox, M.D., M.P.H., director of FDA’s Office of Antimicrobial Products. “For managing this serious disease, it is impor...

FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses
https://www.fda.gov/news-events/press-announcements/fda-clears-new-indications-existing-lyme-disease-tests-may-help-streamline-diagnoses

Jul 28th, 2019 - Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared today are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process ...

FDA approves Feraccru® with a broad label of treating iron deficiency in adults
https://www.shieldtherapeutics.com/wp-content/uploads/2019/07/STX-Feraccru-FDA-approval-26.07.19.pdf

Jul 25th, 2019 - Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product Feraccru® / Accrufer® for the treatment of iron deficiency in adults. With this broad label approval Accrufer® (as the product will be marketed in the USA) has taken a big step towar...

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder
https://tevapharm.com/news/teva_announces_fda_approval_of_airduo_sup_reg_sup_digihaler_trade_fluticasone_propionate_113_mcg_and_salmeterol_14_mcg_inhalation_powder_07_19.aspx

Jul 14th, 2019 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma....

Metoprolol: Uses, Dosage, Side Effects - Drugs.com
https://www.drugs.com/metoprolol.html

Jun 30th, 2019 - Metoprolol is used to treat angina (chest pain) and hypertension (high blood pressure). Learn about side effects, interactions and indications.

Doxycycline: Uses, Side Effects & Dosage Guide - Drugs.com
https://www.drugs.com/doxycycline.html

Jun 30th, 2019 - Doxycycline is an antibiotic used to treat bacterial infections like urinary tract infections, acne and chlamydia. Includes side effects, interactions and indications.

Dosing | HUMIRA (adalimumab)
https://www.humiraconnect.com/psoriatic-arthritis/dosing

Jun 26th, 2019 - Dosing See Important Safety Information, including BOXED WARNING.

Lisinopril: Uses, Dosage, Side Effects & Warnings - Drugs.com
https://www.drugs.com/lisinopril.html

Apr 30th, 2019 - Lisinopril is used to treat hypertension, congestive heart failure and to improve survival after a heart attack. Learn about side effects, interactions and indications.

OPTIMIZER Smart System - P180036
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm634106.htm

Mar 20th, 2019 - The OPTIMIZER Smart System includes an implantable pulse generator (IPG), a charging system and a programmer. The IPG monitors the heart’s activity and delivers non-excitatory electrical signals (cardiac contractility modulation therapy) to the right ventricle of the heart in patients with chronic heart failure.

VENTANA PD-L1 (SP142) Assay - P160002/S009
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm633972.htm

Mar 10th, 2019 - What is it? It is a test done in a laboratory using samples from triple negative breast cancer patients which doctors use to see if patients have programmed cell death ligand (PD-L1) in their cancer. When is it used? To help doctors decide whether atezolizumab is the best treatment choice for their patients. Atezolizumab is a drug that blocks PD-L1. Doctors use atezolizumab in combination wi...

Filgotinib
https://www.glpg.com/filgotinib

Mar 6th, 2019 - Filgotinib is a highly selective JAK1 inhibitor, discovered and developed by Galapagos using its target and drug discovery technology platform. In more than 1,600 patient years of rheumatoid arthritis (RA) and Crohn's disease clinical study experience, filgotinib has shown a rapid onset of action, potentially best-in-class efficacy and favorable findings on safety and tolerability. From a regul...

FDA Approves BIOTRONIK's Ultrathin Orsiro Stent for the Treatment of Coronary Artery Disease
https://www.orsiro.com/us/newsroom/february-22-2019

Feb 21st, 2019 - BIOTRONIK today announced FDA approval of the Orsiro drug-eluting stent (DES) system. Orsiro is the first and only ultrathin DES to outperform the clinical standard, Xience. Orsiro received CE marking in 2011 and has been used to treat more than one million patients worldwide to date. Orsiro's unprecedented clinical performance in the BIOFLOW-V pivotal trial demonstrated significantly lower ra...

CABLIVI (caplacizumab-yhdp) Prescribing Information
http://products.sanofi.us/cablivi/cablivi.pdf

Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Sangia Total PSA Test - P170037
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm630197.htm

Jan 29th, 2019 - The Sangia Total Prostate Specific Antigen (PSA) Test consists of a Cassette Assembly and a Sample Collector. The Sangia Total PSA Test is used as an aid in the diagnosis of prostate cancer. This new test is the first point-of-care test that can deliver PSA results near where the patient is being evaluated, for example at the doctor's office, instead of waiting for lab analysis. The test can be...

Cephalexin Uses, Side Effects & Dosage Guide - Drugs.com
https://www.drugs.com/cephalexin.html

Dec 11th, 2018 - Cephalexin treats infections caused by bacteria, including ear infections, skin infections, and urinary tract infections. Includes cephalexin side effects interactions and indications.

Ramipril: Uses, Dosage, Side Effects & Warnings - Drugs.com
https://www.drugs.com/ramipril.html

Dec 8th, 2018 - Ramipril treats high blood pressure, heart failure, and improves survival after a heart attack. Learn about side effects, interactions and indications.

Losartan: Uses, Dosage, Side Effects & Interactions - Drugs.com
https://www.drugs.com/losartan.html

Dec 4th, 2018 - Losartan (Cozaar) is used to treat high blood pressure and reduce the risk of stroke in certain people with heart disease. Includes side effects, interactions and indications.

MORPHABOND™ ER (morphine sulfate) Prescribing Information
https://dsi.com/prescribing-information-portlet/getPIContent?productName=Morphabond&inline=true

Nov 30th, 2018 - MORPHABOND ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

ROXYBOND (oxycodone hydrochloride) Prescribing Information
https://dsi.com/prescribing-information-portlet/getPIContent?productName=Roxybond&inline=true

Nov 30th, 2018 - ROXYBOND is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.